← Leaderboards
Nick Giannoukakis
Children'S Hosp Pittsburgh/Upmc Hlth Sys
$3,549,775
Attributed
$3,549,775
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2015–17$2M$1.5M$1M$500K$0
'15
'16
'17
Funding mix
By agency
NIH$3,549,775 · 4
By mechanism
UH3$2,276,454 · 1
R21$1,273,321 · 3
Top collaborators
No co-investigators on record.
Most similar at Children'S Hosp Pittsburgh/Upmc Hlth Sys
Same institution · by research overlap
- Dorothy J Becker$40,929,090
Others in their field
Top investigators on “Diabetes Mellitus Therapy”
- David M Nathan · Massachusetts Institute Of Technology$140,313,171
- John M Lachin · George Washington University$134,552,372
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$126,225,488
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Rose A Gubitosi-Klug · Case Western Reserve University$64,112,836
- David Heimbrook · Leidos Biomedical Research, Inc.$56,712,245
Research focus
Diabetes Mellitus TherapyFlow CytometryInflammationGlucose MonitorImpairmentGene TherapyCell PhysiologyB-LymphocytesDiabeticC-PeptideEuglycemic ClampingGap JunctionsGene ExpressionGene Expression ProfilingBlood GlucoseBody WeightCell CountAutoimmunityCellular ImmunityBeta CellDiabetic PatientDendritic CellsImmuneInsulin Resistance
Grant awards (8)
CXCR2 antagonism in the immunometabolic regulation of type 2 diabetes$301,793
R21 · FY2017 · TR · contact PI
Anti-inflammatory Small Drug as Adjunctive Therapy to Improve Glucometabolic Variables in Obese, Insulin-Resistant Type 2 Diabetic Patients$1,113,043
UH3 · FY2016 · TR · contact PI
CXCR2 antagonism in the immunometabolic regulation of type 2 diabetes$341,528
R21 · FY2016 · TR · contact PI
Anti-inflammatory Small Drug as Adjunctive Therapy to Improve Glucometabolic Variables in Obese, Insulin-Resistant Type 2 Diabetic Patients$1,163,411
UH3 · FY2015 · TR · contact PI
Prevention of Type I Diabetes Mellitus using a Cell Vac*$175,000
R21 · FY2002 · DK
Anti-apoptotic gene therapy: Islet allotransplantation$140,000
R21 · FY2002 · DK
Type I Diabetes Mellitus Prevention using Cell Vaccine$175,000
R21 · FY2001 · DK
Anti-apoptotic gene therapy: Islet allotransplantation$140,000
R21 · FY2001 · DK